Pharma Exclusives Pressreleases
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
Friday, May 09, 2025Eli Lilly and Company and Purdue University announced today a significant expansion of their longstanding alliance with Lillys planned investment of up to million in the collaboration over the next eight years
Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston
Thursday, May 08, 2025H Lundbeck AS Lundbeck will present key pipeline data and patient perspectives from the phase II AMULET trial investigating amlenetug as a potential new treatment option targeting the rare neurological disorder
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
Thursday, May 08, 2025Cybin Inc a clinicalstage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative nextgeneration treatment options today announced that the United States
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
Wednesday, May 07, 2025Gilead Sciences Inc today announced new data from multiple analyses which reinforce that Livdelzi seladelpar known as Lyvdelzi in the European Union is effective and generally welltolerated for the treatment
GeneFab and RegCell Announce Strategic Partnership to Advance Autoimmune Cell Therapy into U.S. Clinical Trials
Wednesday, May 07, 2025GeneFab a nextgeneration cell and gene therapyfocused contract research development and manufacturing organization CRDMO has partnered with RegCell a biotech company advancing regulatory T cell Treg therapies for autoimmune diseases
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
Wednesday, May 07, 2025GRI Bio Inc a biotechnology company advancing an innovative pipeline of Natural Killer T NKT cell modulators for the treatment of inflammatory fibrotic and autoimmune diseases today announced that enrollment for the week interim analysis
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
Tuesday, April 29, 2025AbbVie today announced the US Food and Drug Administration FDA has approved RINVOQ upadacitinib mg once daily for the treatment of adults with giant cell arteritis GCA This comes after the European Commission recently granted marketing authorization...
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
Monday, April 28, 2025Eton Pharmaceuticals Incan innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases today announced the submission of a New Drug Application NDA to the US Food and Drug Administration
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics
Monday, April 28, 2025Thermo Fisher Scientific the world leader in serving science is employing an enhanced platform technology and a new CHO K cell line that can reduce timelines to Investigational New Drug IND filing from to nine months
Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers’ Manufacturing
Thursday, April 24, 2025Thermo Fisher Scientific Inc the world leader in serving science will invest an additional billion in the United States over the next four years strengthening American innovation manufacturing and economic competitiveness across the life sciences se...
